Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ALEXION PHARMACEUTICALS, INC.

(ALXN)
  Report
SummaryQuotesChartsNewsRatingsCompanyFinancials 
Business Summary
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on discovering, development and commercialization of medicines. The CompanyÔÇÖs marketed products include ULTOMIRIS, SOLIRIS (eculizumab), STRENSIQ (asfotase alfa), KANUMA (sebelipase alfa) and ANDEXXA (coagulation Factor Xa - [recombinant] inactivated-zhzo). Its ULTOMIRIS product is a long-acting C5 inhibitor, that works by inhibiting the C5 protein in the terminal complement cascade. Its SOLIRIS product is a humanized monoclonal antibody that blocks terminal activity at the doses prescribed. Its Strensiq product is a targeted enzyme replacement therapy for patients with Hypophosphatasia (HPP). Its Kanuma product is a recombinant form of the human lysosomal acid lipase (LAL) enzyme. Its ANDEXXA product is a reversal agent for patients treated with rivaroxaban or apixaban.

Number of employees : 3 837 people.
Sales per Business
20192020Delta
Biopharmaceutical4 990.00100.7%6 069.10100.1% +21.63%
USD in Million
Sales per region
20192020Delta
United States2 762.5055.8%3 604.0059.4% +30.46%
Europe1 206.1024.3%1 326.9021.9% +10.02%
Asia Pacific528.4010.7%663.6010.9% +25.59%
Rest of the World493.0010%474.607.8% -3.73%
USD in Million
Managers
Name Title Age Since
George Llado Chief Information Officer & Senior Vice President - 2015
Indrani Franchini Chief Compliance Officer & Executive VP 49 2017
Rana Strellis SVP-Global Culture & Social Responsibility - -
Gianluca Pirozzi, Dr. Head-Clinical Development, Hematology & Nephrology 44 2019
Uzair Qadeer Chief Diversity Officer & Senior Vice President - 2020
Becky Lillie Senior Vice President-Leader & Innovation - -
Tamar Thompson Vice President-US Government Affairs & Policy 47 2019
Martine Zimmermann, Dr. Senior VP & Head-Global Regulatory Affairs - 2016
Morgan Sanford Chief of Staff - -
Daniel A. Bazarko Chief Accounting Officer & Senior Vice President - -
Shareholders
NameEquities%
The Vanguard Group, Inc. 19,459,993 8.80%
SSgA Funds Management, Inc. 10,033,808 4.54%
Farallon Capital Management LLC 7,707,500 3.49%
ClearBridge Investments LLC 5,866,154 2.65%
Davidson Kempner Capital Management LP 5,473,378 2.48%
Adage Capital Management LP 5,238,014 2.37%
Pentwater Capital Management LP 4,933,200 2.23%
Millennium Management LLC 4,829,380 2.19%
BlackRock Fund Advisors 4,737,068 2.14%
UBS O'Connor LLC 4,428,122 2.00%
Company contact information
Alexion Pharmaceuticals, Inc.
121 Seaport Boulevard
Boston, MA 02210

Phone : +1.475.230.2596
Fax : +1.203.271.8198
Web : http://www.alexion.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Alexion Pharmaceuticals, Inc.